Targeting the Oncoprotein MDMX as a Novel Treatment for Triple Negative Breast Cancer
Targeting the Oncoprotein MDMX as a Novel Treatment for Triple Negative Breast Cancer
批准号:
nhmrc : GNT1123057
负责人:
A/Pr Elgene Lim
金额:
$56.17万
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2017
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2017-01-01 至 --
中文摘要
乳腺癌(BRCA)是全球女性癌症死亡的主要原因。无法对目前的治疗方法做出反应的Brca患者的结果最差。基于我们的新发现,我们提出了一种治疗这些癌症的新策略。我们的两个蛋白质靶点是:(1)MDMX,我们发现它与其伴侣一起驱动BRCA,(2)突变的p53,它会导致癌症扩散。我们计划直接针对这些攻击性BrCA的驱动因素,使用在一些癌症的试验中个别显示出巨大前景的新药
英文摘要
Breast cancer (BrCa) is a leading cause of cancer death in women worldwide. BrCas unable to respond to current therapies have the worst outcomes. We propose a novel strategy to treat these cancers, based on our new findings. Our two protein targets are: (1) MDMX, that we found drives BrCa with its partner, (2) mutant p53, which causes cancer spread. We plan to directly target these drivers of aggressive BrCas, using new drugs that individually show great promise in trials in a number of cance
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pushing AR toward better outcomes in breast and prostate cancers
-
批准号:nhmrc : 1145777
-
项目类别:Project Grants
-
资助金额:$67.53万
-
财政年份:2018
-
负责人:A/Pr Elgene Lim
-
依托单位:
Development of a novel and highly selective CDK4/6 inhibitor for treating cancer
-
批准号:nhmrc : GNT1135682
-
项目类别:Development Grants
-
资助金额:$117.12万
-
财政年份:2018
-
负责人:A/Pr Elgene Lim
-
依托单位:
Development of a novel and highly selective CDK4/6 inhibitor for treating cancer
-
批准号:nhmrc : 1135682
-
项目类别:Development Grants
-
资助金额:$79.19万
-
财政年份:2018
-
负责人:A/Pr Elgene Lim
-
依托单位:
Centre for Translational Breast Cancer Research (TransBCR): delivering laboratory discoveries to the clinic
-
批准号:nhmrc : GNT1153049
-
项目类别:Centres of Research Excellence
-
资助金额:$249.64万
-
财政年份:2018
-
负责人:A/Pr Elgene Lim
-
依托单位:
Targeting the Oncoprotein MDMX as a Novel Treatment for Triple Negative Breast Cancer
-
批准号:nhmrc : 1123057
-
项目类别:Project Grants
-
资助金额:$38.34万
-
财政年份:2017
-
负责人:A/Pr Elgene Lim
-
依托单位:
The clinical significance of sex hormone crosstalk in estrogen receptor positive breast cancer.
-
批准号:nhmrc : GNT1130077
-
项目类别:Project Grants
-
资助金额:$100.9万
-
财政年份:2017
-
负责人:A/Pr Elgene Lim
-
依托单位:
Four dimensional epigenome remodelling: implications for endocrine resistance in breast cancer
-
批准号:nhmrc : 1128916
-
项目类别:Project Grants
-
资助金额:$56.54万
-
财政年份:2017
-
负责人:A/Pr Elgene Lim
-
依托单位:
The clinical significance of sex hormone crosstalk in estrogen receptor positive breast cancer.
-
批准号:nhmrc : 1130077
-
项目类别:Project Grants
-
资助金额:$68.95万
-
财政年份:2017
-
负责人:A/Pr Elgene Lim
-
依托单位:
Development of vinorelbine as a tablet based therapy to cure ectopic pregnancies
-
批准号:nhmrc : GNT1123274
-
项目类别:Project Grants
-
资助金额:$36.16万
-
财政年份:2017
-
负责人:A/Pr Elgene Lim
-
依托单位:
Development of vinorelbine as a tablet based therapy to cure ectopic pregnancies
-
批准号:nhmrc : 1123274
-
项目类别:Project Grants
-
资助金额:$24.68万
-
财政年份:2017
-
负责人:A/Pr Elgene Lim
-
依托单位:
Four dimensional epigenome remodelling: implications for endocrine resistance in breast cancer
-
批准号:nhmrc : GNT1128916
-
项目类别:Project Grants
-
资助金额:$82.86万
-
财政年份:2017
-
负责人:A/Pr Elgene Lim
-
依托单位:
The identification of novel targets and therapeutic agents in the treatment of triple negative breast cancer.
-
批准号:nhmrc : 1013525
-
项目类别:Early Career Fellowships
-
资助金额:$24.4万
-
财政年份:2011
-
负责人:A/Pr Elgene Lim
-
依托单位:
海外基金